Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 30;9(4):1888.
doi: 10.4081/jphr.2020.1888. eCollection 2020 Oct 14.

Waiting for Godot: A cross sectional survey based analysis of the hydroxychloroquine prophylaxis strategy against COVID-19 in India

Merlin Moni  1 , Thushara Madathil  2 , Rahul Palabatla  3 , Sabarish Balachandran  4 , Fabia Edathadathil  5 , Georg Gutjahr  6 , Sai B Madathil  7 , Rajesh Pai  8 , Beena Kv  8 , Aveek Jayant  2 , Dipu T Sathyapalan  9
Affiliations

Waiting for Godot: A cross sectional survey based analysis of the hydroxychloroquine prophylaxis strategy against COVID-19 in India

Merlin Moni et al. J Public Health Res. .

Abstract

Background: India currently has the second largest burden of infections due to COVID-19. Health Care Worker (HCW) shortages are endemic to Indian healthcare. It should therefore be a huge priority to protect this precious resource as a critical component of the systemic response to this pandemic. Advisories from the Indian Council of Medical Research (ICMR) have focused on using hydroxychloroquine prophylaxis against COVID-19 in at risk HCW. This prophylaxis strategy has no evidence. In further jeopardy there appear to insubstantial attempts to build this evidence as well. In this connection, we commissioned a survey within our Institution to estimate the penetration of hydroxychloroquine (HCQ) use and use this to statistically model the impact of current ongoing studies in India. We also briefly review the literature on HCQ prophylaxis for COVID-19. Design and methods: A structured survey designed using RedCAP application was disseminated among healthcare professionals employed at an academic referral tertiary care centre via online social media platforms. The survey was kept open for the entire month of June 2020. The survey was additionally used to statistically model the size of studies required to comprehensively address the efficacy of HCQ in this setting. Results: 522 responses were received, of which 4 were incomplete. The ICMR strategy of 4 or more doses of HCQ was complete only in 15% of HCW in our survey. The majority of respondents were doctors (238, 46%). Amongst all category of responders, only 12% (n=63) received the full course. A majority of those who initiated the chemoprophylaxis with HCQ turned out to be medical professionals (59/63) with neither nurse nor other categories of healthcare workers accessing the medication. The respondents of our institutional survey did not report any life-threatening side effects. Presuming efficacy as per ICMR modelling for new registry trial on the lines of the published case control study, equal allocation between cases and controls and assuming a RR of 1.3.6, the power of such a study would be very low for n=2000 for event rates from 2.5-12.5%. Conclusion: We report the low penetration of HCQ chemoprophylaxis among the healthcare workers of our institution. We highlight the inherent drawbacks in the study design of current national COVID related trial based on the statistical modelling of our survey results and published literature, and thereby emphasis the need of evidence-based strategies contributing to research policy at national level.

Keywords: COVID trial designs; Hydroxychloroquine chemoprophylaxis; SARS-CoV-2.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
HCQ prophylaxis amongst healthcare workers by role : intra-institutional survey report.
Figure 2.
Figure 2.
HCQ prophylaxis amongst healthcare workers by age: intra-institutional survey report.
Figure 3.
Figure 3.
HCQ chemoprophylaxis distribution among patients with co-morbidities: intra-institutional survey report.
Figure 4.
Figure 4.
Sample size modelling for different event rates assuming equal allocation.
Figure 5.
Figure 5.
Sample size modelling for different event rates based on institutional26 and ICMR reported HCQ prophylaxis penetration.
See this image and copyright information in PMC

References

    1. Armocida B, Formenti B, Ussai S, et al. The Italian health system and the COVID-19 challenge. Lancet Public Health 2020;5:e253. doi: 10.1016/S2468-2667(20)30074-8 - PMC - PubMed
    1. Tanne JH, Hayasaki E, Zastrow M, et al. Covid-19: how doctors and healthcare systems are tackling coronavirus worldwide. BMJ 2020;368:m1090. doi: 10.1136/bmj.m1090 - PubMed
    1. Uddin M, Mustafa F, Rizvi TA, et al. SARS-CoV-2/COVID- 19: Viral Genomics, epidemiology, vaccines, and therapeutic interventions. Viruses 2020;12:526. doi: 10.3390/v12050526 - PMC - PubMed
    1. Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial. Int J Antimicrob Agents 2020;56:105949. doi: 10.1016/j.ijantimicag.2020.105949 - PMC - PubMed
    1. Lee SH, Son H, Peck KR. Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals? Int J Antimicrob Agents 2020;55: 105988. doi: 10.1016/j.ijantimicag.2020.105988 - PMC - PubMed

LinkOut - more resources